

GOVERNMENT OF PAKISTAN
THE PATENT OFFICE
2nd Floor, Kandawala Building,
M.A. Jinnah Road,
Karachi

No.2/2/2003-F.Sec.

Dated 01-2-2007

To,

The Manager,
Printing Corporation of Pakistan Press,
University Road,
Karachi

Subject: **WEEKLY NOTIFICATION OF PATENT OFFICE FOR THE
WEEKENDING 23-9-2006 TO BE PUBLISHED ON 02-1-2007 IN
THE GAZETTE OF PAKISTAN PART-V.**

A manuscript copy of the weekly notification regarding application filed application accepted and scaling fee due etc., is forwarded herewith to be published in the next issue of the Gazette of Pakistan Part-V without fail.

(Mrs. Yasmeen Abbasi)
Controller of Patents & Designs
Ph: 9215488

ENCL:

NEW APPLICATIONS FOR THE PATENTS

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000.

1190/2006	<u>18-09-2006</u> Nestec S.A, Switzerland, (Priority 20-9-05 Europe)	“ Water dispersible composition and method for preparing same ”
1191/2006	Wyeth, USA (Priority 24-10-03 USA) Divisional	“ Pharmaceutically acceptable salts of dihydrobenzofuranyl alkanamine derivatives useful for treating cns disorders”
1192/2006	Altana Pharma AG., Germany	“ Novel sulphonylpyrroles”
1193/2006	M. Sherif Danish., USA (Priority 19-9-05 USA)	“ Programmable portable media player for guidance, training and games”
1194/2006	Emisphere Technology Inc., USA (Priority 19-9-05 USA)	“ Crystalline polymorphic forms of the di-sodium salt of n-(5chlorosalicyloyl)-8-aminocaprylic acid”
1195/2006	<u>19-9-2006</u> Otsuka Pharmaceutical Factory, Inc., Japan (Priority 30-9-05 Japan)	“ Cover for being mounted on a multi-compartment infusion bag”
1196/2006	1. AstraZeneca AB., Sweden 2. NPS Pharmaceuticals, Inc., USA (Priority 29-9-05 USA)	“ New compounds for the treatment of neurological, psychiatric or pain disorders”
1197/2006	Dollar Industries Pakistan Karachi, Pakistan	“ Marker pen with improved ink filling arrangement”
1198/2006	Daniel Serrano Gil,	“ A composition to be administered to a

	Spain (Priority 19-9-05 Spain)	mammal or to a human being”
1199/2006	Pfizer Limited., UK (Priority 21-9-05 USA)	“ Carboxamide derivatives as muscarinic receptor antagonists”
1200/2006	Pfizer Products Inc. USA (Priority 22-9-05 USA)	“ Imidazole compounds for the treatment of neurological disorders”
1201/2006	Eisai Co. Ltd., Japan (Priority 26-12-03 Japan) Divisional	“ Salts of compound comprising 1,2-di(cyclic) substituted benzene, pharmaceutical compositions thereof for use in therapy”
1202/2006	Theravance, Inc., USA (Priority 9-9-03 USA) Divisional	“ Salts of an amino-substituted ethylamino β 2 adrenergic receptor agonist compound, method of preparation and pharmaceutical compositions thereof”
1203/2006	AstraZeneca UK Limited., United Kingdom (Priority 13-7-01 Japan) Divisional	“ A halogenopyrimidine compound and method for preparation thereof”
1204/2006	AstraZeneca UK Limited., United Kingdom (Priority 13-7-01 Japan) Divisional	“ A method of preparing an aminopyrimidine compound”
1205/2006	AstraZeneca UK Limited., United Kingdom (Priority 13-7-01 Japan) Divisional	“ Hydroxypyrimidine compound and process for the preparation thereof”
1206/2006	AstraZeneca UK Limited., United Kingdom (Priority 13-7-01 Japan) Divisional	“ A Dihydropyrimidinone compound and process for the preparation thereof”
1207/2006	AstraZeneca UK Limited., United Kingdom	“ An organic sulfonyloxypyrimidine compound and process for their

	(Priority 13-7-01 Japan) Divisional	preparation thereof”
1208/2006	AstraZeneca UK Limited., United Kingdom (Priority 13-7-01 Japan) Divisional	“ A process for preparing a salt of 2-(N-methyl-N-methanesulfonylamino)p yrimidine”
	<u>20-9-2006</u>	
1209/2006	Chaiseri Metal & Rubber Co., Ltd. Thailand (Priority 06-6-06 Europe)	“ Track shoe assembly for tracked vehicle”
1210/2006	AstraZeneca AB Sweden (Priority 30-9-05 GB)	“ Chemical Compound”
1211/2006	AstraZeneca AB Sweden (Priority 30-9-05 GB)	“ Chemical Process”
1212/2006	AstraZeneca AB Sweden (Priority 30-9-05 USA)	“ Chemical Compounds”
1213/2006	1. SB Pharmco Puerto Rico Inc. Puerto Rico (Priority 22-9-05 USA)	“ Method of improvement of cognitive function”
1214/2006	1. SB Pharmco Puerto Rico Inc., Puerto Rico (Priority 22-9-05 USA)	“ Pharmaceutical composition for improvement of cognitive function”
1215/2006	Honda Motor Co, Ltd., Japan (Priority 31-10-06 Japan)	“ Fuel supply unit”
1216/2006	Aventis Pharma SA., France (Priority 27-9-05 France)	“ Novel benzimidazole and benzothiazole derivatives, preparation process therefore, application thereof as medicaments, pharmaceutical compositions and novel use especially as cmet inhibitors”

1217/2006	AstraZeneca AB Sweden (Priority 21-9-05 USA)	“ Alkyl nitrile quinolines”
1218/2006	AstraZeneca AB Sweden (Priority 29-9-05 Sweden)	“ New compounds I”
1219/2006	AstraZeneca AB Sweden (Priority 29-9-05 Sweden)	“ New compounds II”
<u>21-9-2006</u>		
1220/2006	1. Prof. Dr. Bina S. Siddiqui 2. Prof. Dr. S. Naeem-ul-Hasan Naqvi 3. Dr. Syed Tariq Ali and 4. Prof. Dr. Shaheen Faizi H.E.J. Research Institute of Chemistry, University of Karachi,	“ Biosal-A pesticidal composition based on the whole fruits of azadirachta indica A. juss”
1221/2006	1. Prof. Dr. Bina S. Siddiqui 2. Dr. Syed Tariq Ali and 3. Dr. Jafar Nazir Usmani H.E.J. Research Institute of Chemistry University of Karachi,	“ Development of a method for the production of bio-diesel”
1222/2006	1. Prof. Dr. Bina S. Siddiqui 2. Dr. Syed Tariq Ali 3. Prof. Dr. Shaheen Faizi and 4. Syed Kashif Ali H.E.J Research Institute of Chemistry University of Karachi,	“ Agrosal-A pesticidal composition based on the whole dry fruits (or kernel) of azadirachta indica A. juss”
1223/2006	N.V. Organon, Netherlands (Priority 23-9-05 Europe)	“ Phenyl-6-substituted-pyrimidine-2-carbonitril derivatives”
1224/2006	AstraZeneca AB Sweden	“ Alkyl Sulfoxide quinolines”

(Priority 21-9-05 USA)

22-9-2006

1225/2006	Otsuka Pharmaceutical Co, Ltd. Japan (Priority 31-10-03 Japan)	“ A Pharmacologically acceptable salt of 2,3-dihydro-6-nitroimidazo[2,1-b]oxazole compound”
1226/2006	Eisai Co. Ltd., Japan Divisional	“ A bis lysine salt of (2R,3R)-3-[4-(4-cyanophenyl)thiazol-2-(2,4-difluorophenyl)-1-(1H-1,2,4-triazol-1-yl)-2-[(dihydrogen phosphonoxy)methoxy]butane”
1227/2006	AstraZeneca AB Sweden (Priority 01-2-02 Europe) Divisional	“ 4-(4-fluro-2-methylindol-5-yloxy)-7-hydroxy-6-methoxyquinazoline”
1228/2006	AstraZeneca AB Sweden (Priority 01-2-02 Europe) Divisional	“ Process for the preparation of 5-bromo-7-azaindole”
1229/2006	AstraZeneca AB Sweden (Priority 01-2-02 Europe) Divisional	“ Process for the preparation of 5-bromo-7-azaindole”
1230/2006	AstraZeneca AB Sweden (Priority 01-2-02 Europe) Divisional	“ Process for the production of 5-methoxy-7-azaindole”
1231/2006	SmithKline Beecham Biologicals S.a., Sweden (Priority 01-2-2002 EP) Divisional	“ A salt of quinazoline compound, process for its preparation and pharmaceutical composition containing it”
1232/2006	Bristol-Myers Squibb Company, USA (Priority 22-9-05 USA)	“ Fused heterocyclic compounds useful as kinase modulators”

1233/2006	<u>23-9-2006</u> Au Vitronic Limited, Karachi, Pakistan	“ A process for manufacturing of wall panels by using fibre gel & marble powder based composition raw material”
1234/2006	Tanabe Seiyaku Co., Ltd. Japan (Priority 20-12-03 UK) Divisional	“ A pharmaceutically acceptable derivative or salt of a phenylalanine compound and a pharmaceutical composition comprising thereof “
1235/2006	Honda Motors Co., Ltd. Japan (Priority 10-11-05 Japan)	“ Tail Lamp structure”
1236/2006	Pierre Fabre Medicament France (Priority 27-9-05 France)	“ Method for preparing (3-chloro-4-fluorophenyl)-(4-fluoro-4- { [5-methyl-pyrimidin-2-ylmethyl)-amino]-methyl}-piperidin-1-yl)-methanone and novel intermediate pyrimidine derivatives”

SEALING FEES DUE

Notice is hereby given that the Patent may now be sealed on the application referred to below if it is desired that Patent should be sealed a request on the prescribed Form-10 accompanied by the fee of Rs.2250/- should be sent to the Controller of Patents and Designs, The Patent Office, Karachi.

139068	Mitsui Chemicals, Inc., Japan	655/2004
139069	Tianjin Tasly Pharmaceutical Co., Ltd., China	656/2004

139070	Aventis Pharma S.A., France	662/2004
139071	Sanofi-Aventis Deutschland GmbH, Germany	664/2004
139072	Otsuka Pharmaceutical Co. Ltd., Japan	665/2004
139073	Mitsui Chemicals, Inc., Japan	514/2006
139074	Mitsui Chemicals, Inc., Japan	515/2006
139075	Mitsui Chemicals, Inc., Japan	516/2006
139076	Mitsui Chemicals, Inc., Japan	517/2006
139077	Mitsui Chemicals, Inc., Japan	518/2004

(Mrs. Yasmeen Abbasi)

Controller of Patents & Designs

Tel: 9215488